Promising Outcomes from Encaleret's Phase 2 Study
Recent findings suggest that encaleret has revolutionized the treatment landscape for those grappling with post-surgical hypoparathyroidism. In a Phase 2 proof-of-concept study, a remarkable 80% of participants managed to reach normal levels of blood and urine calcium within just five days of starting encaleret, in stark contrast to those on traditional therapies, who saw no improvement at the outset.
BridgeBio Pharma, Inc., a pioneering biopharmaceutical company focused on innovative treatments for genetic diseases, has been making waves with its investigational therapy encaleret. This oral medication demonstrated an impressive safety profile with no serious adverse effects reported during the study. These findings foster excitement within the medical community about potential advances in chronic hypoparathyroidism management.
Understanding Post-Surgical Hypoparathyroidism
Post-surgical hypoparathyroidism is an often complicated condition characterized by the body's inability to maintain adequate calcium levels. Iris Hartley, M.D., an endocrinologist involved in the research, noted that balancing blood and urine calcium in patients is a significant challenge. Typical treatments involve calcium and active vitamin D, aiming to maintain low-normal blood calcium levels. However, achieving this balance is difficult for many patients, leading to disruptive symptoms from low calcium levels, such as muscle spasms and fatigue, alongside the risk of kidney injuries from high urine calcium levels.
Hartley emphasized the critical need for more effective treatment options, and the positive results from encaleret have illuminated a path towards better control over calcium levels. The ease of an oral treatment form adds an element of convenience to management strategies.
Insights from Phase 2 Trial Results
The proof-of-concept study involved ten participants, all dealing with post-surgical hypoparathyroidism, who were given encaleret at a dose of 162 mg twice daily for up to five days following cessation of calcitriol. Blood calcium levels were then carefully monitored and adjusted. The outcomes were overwhelmingly positive, showcasing significant reductions in calcium excretion for most participants.
Key Study Findings
- Encaleret led to a swift and lasting decrease in the amount of calcium excreted via urine for nine of the participants.
- The trial confirmed that 80% of the participants reached normal blood and urine calcium levels, while those receiving conventional treatment remained at 0% improvement.
- The positive outcomes strongly advocate for further studies on encaleret as a convenient oral therapeutic alternative for chronic hypoparathyroidism.
Scott Adler, M.D., Chief Medical Officer at Calcilytix, a BridgeBio affiliate, echoed these sentiments, highlighting how encaleret acts independently of parathyroid hormone (PTH) to normalize calcium levels. As a result of these encouraging findings, the company plans to launch a registrational clinical study focused on chronic hypoparathyroidism commencing in 2026.
Additional Studies and Developments
During the recent American Society for Bone and Mineral Research (ASBMR) Annual Meeting, additional preclinical studies on infigratinib were showcased. These studies revealed that low doses of infigratinib noticeably enhanced bone growth in models of hypochondroplasia, as well as improved skull development in a Crouzon/Pfeiffer syndrome model. This support underscores BridgeBio's commitment to exploring diverse treatment options for skeletal conditions.
About BridgeBio Pharma, Inc.
Founded in 2015, BridgeBio Pharma, Inc. has established itself as a leader in the biopharmaceutical space, with a firm commitment to addressing genetic diseases through innovative therapies. The company’s initiatives span from initial scientific research to advanced clinical trials, as it strives to make substantial advances in genetic medicine accessible for patients who need them most.
For more information about BridgeBio and its pipeline, please feel free to reach out through their media contact, Bubba Murarka, at (650)-789-8220 or via email at contact@bridgebio.com.
Frequently Asked Questions
1. What is encaleret's primary use?
Encaleret is primarily used as a treatment for post-surgical hypoparathyroidism, helping to normalize calcium levels in the body.
2. How quickly does encaleret work?
In the Phase 2 study, 80% of participants saw normalization of calcium levels within five days of treatment initiation.
3. Are there any reported side effects of encaleret?
The Phase 2 study indicated that encaleret was well-tolerated, with no serious adverse events reported.
4. When will additional studies on encaleret be conducted?
BridgeBio plans to start a registrational clinical study of encaleret in chronic hypoparathyroidism in 2026.
5. What other therapies is BridgeBio developing?
In addition to encaleret, BridgeBio is exploring therapies like infigratinib, which has shown potential in enhancing bone growth across various conditions.
